Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2013 16:30 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Teleconference and Webcast

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a teleconference and webcast with management to provide a...
August 06, 2013 09:15 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Larry J. Singer as Vice President, Manufacturing

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that Larry J. Singer has joined the company as vice president, Manufacturing. Mr....
July 17, 2013 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Three New Additions to Its Senior Leadership Team

SOUTH SAN FRANCISCO, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company has added three new executives to its leadership team: senior vice...
July 02, 2013 09:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Present at the Eighth Annual JMP 2013 Global Healthcare Securities Conference

SOUTH SAN FRANCISCO, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the eighth annual JMP 2013 Global...
June 18, 2013 08:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology

SOUTH SAN FRANCISCO, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that population pharmacokinetic (PK) modeling and dosing simulations were...
June 03, 2013 09:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Acquires Worldwide Rights to BUPHENYL

SOUTH SAN FRANCISCO, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the completion of its acquisition of BUPHENYL® (sodium phenylbutyrate)...
May 29, 2013 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Jefferies 2013 Global Healthcare...
May 16, 2013 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)

SOUTH SAN FRANCISCO, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index®...
May 09, 2013 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces First Quarter 2013 Operating Results

First Net Sales of RAVICTI Post-approval Reported at $0.8 Million Strong Cash Position of $102.7 million SOUTH SAN FRANCISCO, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc....
May 06, 2013 18:36 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Report First Quarter 2013 Financial Results After Market on May 9, 2013

SOUTH SAN FRANCISCO, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report financial results for the first quarter 2013 ended March 31,...